

# EuroSIDA Newsletter

October 2014



## ANNOUNCEMENTS

### The new EuroSIDA cohort

The EuroSIDA study aims at enrolling 5000 HIV/HCV co-infected patients into the new EuroSIDA Cohort 10, **so far 1094 patients have been enrolled**. 9 centres have reached their enrollment target and the EuroSIDA team would like to thank these sites for their professional work done to complete the enrollment process.

Ethical approval has been obtained by 58 out of 70 centres, which are hereby ready to enrol patients. **We encourage you to please enroll the targeted number of patients within three months after obtaining your EC approval.**

Of the 58 centres that have obtained EC approval 46 have started to register the enrolled patients into the electronic CRF REDCap system. It is our experience that many centres fill out the case-report forms in batches, but for the coordinating center at CHIP to be able to monitor the progress of enrolment, **we encourage you to complete at least section A (demography and HIV status) of the enrolment forms** shortly after the informed consent has been obtained.

### Monitoring enrolment in electronic submission sites

As the EuroSIDA coordination team monitors the enrolment in the new EuroSIDA cohort closely, we encourage the centres that are delivering the data in an electronic data file, to please update the EuroSIDA coordination team about **enrolment progression once every month**.

### REDCap

We have had a number of questions concerning how to enter the REDCap system. Please be aware that CHIP are working with more than one REDCap system and for EuroSIDA the link to be used is: <https://www.chip-crf.info/redcap/index.php?action=myprojects>

If you have any questions regarding enrolment or completion of the case-report forms in REDCap, please send an email to Lars Peters, [lars.peters@regionh.dk](mailto:lars.peters@regionh.dk)

## EuroSIDA investigator meeting at the HIV Drug Therapy 2014 Conference in Glasgow

EuroSIDA has planned an **investigator meeting at the HIV Drug Therapy 2014** conference in Glasgow. We kindly invite all

### Dataset 40

The **deadline for returning dataset 40 was 1st August 2014**.

We kindly ask centres that have not yet returned the forms to do it as soon as possible in order for the EuroSIDA team to be able to prepare for dataset 41.

So far the Coordinating Centre has received about 8,000 DS 40 forms of the 10,000 forms sent out, which gives a return percentage of 80%.

### Study group

The studygroup on the CHIP webpage has recently been updated. Kindly confirm that the study group listed on the website is correct: <http://www.cphiv.dk/Ongoing-Studies/EuroSIDA/Study-group> and inform the EuroSIDA team if there are changes to be made to the study group.

### New e-mail address

Please note that we have changed e-mail addresses. You can reach us at [EuroSIDA.rigshospitalet@regionh.dk](mailto:EuroSIDA.rigshospitalet@regionh.dk). E-mails sent to our old addresses will be forwarded.

### Update from EuroCoord

Please find the latest from EuroCoord at: newsletter at [www.eurocoord.net](http://www.eurocoord.net)



EuroSIDA investigators to participate. The meeting will take place on **Wednesday 5th of November from 12.00-13.00 in the 'Morar' room**. We hope to see many of you there for an update of the new cohort and the ongoing activities within EuroSIDA. The EuroSIDA team including our IT specialist will be represented to clarify any questions regarding the new electronic CRF system, REDCap. **Please confirm your participation by email: [eurosidea.rigshospitalet@regionh.dk](mailto:eurosidea.rigshospitalet@regionh.dk)**

### **EuroSIDA at the HIV Drug Therapy 2014 Conference in Glasgow, 02-06 November 2014**

It is a pleasure to inform you that EuroSIDA – as usual – is well profiled at the Glasgow conference. This time, there will be two oral and four poster presentations.

#### **Oral presentations in Glasgow:**

**Oral session No. O234:** Tuesday 4th November 14.45-15.00: *Regional differences in self-reported HIV care and management in the EuroSIDA study*. Presented by Kamilla Laut.

**Oral session No. O313:** Wednesday 5th November 09.05-09.20: *Predictive value of Prostate Specific Antigen for prostate cancer: a nested case control study in EuroSIDA*. Presented by Leah Shepherd

#### **Posters in Glasgow:**

**Poster No. P029:** *The prevalence and predictive value of dipstick protein (DUP) in HIV-positive persons in Europe*. Presented by Amanda Mocroft

**Poster No. P153:** *Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death*. Presented by Maria Casadellà Fontdevila

**Poster No. P278:** *Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression*. Presented by Josep M Libre

**Poster No. P205:** *Detection of Resistance Mutations and CD4 Slopes in Individuals Experiencing Sustained Virological Failure*. Presented by Anna Schultze

## **PUBLICATIONS**

Publications since last newsletter August 2014

**HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective.** L Peters, A Mocroft, J Lundgren, D Grint, O Kirk, J Rockstroh. BMC Infect Dis. 2014; 14(Suppl 6): S13.

**A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.** A Mocroft, P Reiss,

A Rakhmanova, D Banhegyi, AN Phillips, S De Wit, M Ristola, JD Lundgren, J Garup, O Kirk, EuroSIDA in EuroCOORD. Infection. 2014 Aug;42(4):757-62.

**Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.** Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. AIDS. 2014 Sep 24;28(15):2297-306.

## IN PRESS

**Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based antiretroviral therapy: A multi-cohort European case-control study using centralized ultrasensitive 454 pyrosequencing.** A Cozzi-Lepri, M Noguera-Julian F Di Giallonardo, R Schuurman, M Däumer, S Aitken, F Ceccherini-Silberstein, A d'Arminio Monforte, A Geretti, C Booth, R Kaiser, C Michalik, K Jansen, P Bellecave, B Masquelier, R Kouyos, E Castro, H Furrer, A Schultze, H Günthard, F Brun-Vézinet, R Paredes, K Metzner. Journal of Antimicrobial Chemotherapy. [in press]

**The effects of HIV-1 subtype and ethnicity on CD4 decline in antiretroviral naïve patients: a Canadian-European collaborative cohort study.** M Klein et al. CMAJ Open. [in press]

**Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.** AH Borges, JD Lundgren, A Ridolfo, C Katlama, F Antunes, A Grzeszczuk, A Blaxhult, VM Mitsura, M Doroana, M Battegay, P Gargalianos, A Mocroft, on behalf of EuroSIDA in EuroCOORD. AIDS 2014 [in press]

---

EuroSIDA Coordinating Centre. Rigshospitalet, University of Copenhagen. CHIP, Department of Infectious Diseases and Rheumatology, Section 2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: [EuroSIDA.rigshospitalet@regionh.dk](mailto:EuroSIDA.rigshospitalet@regionh.dk)

Web: [www.regionh.dk](http://www.regionh.dk) [www.chip.dk](http://www.chip.dk)